RPG Life Sciences acquiring Raghava Life Sciences’ API, intermediates business for ₹135 crore
RPG Life Sciences is acquiring the API and intermediates business of Raghava Life Sciences for ₹135 crore through a slump sale. This acquisition is part of a strategic effort to expand the company's manufacturing capacity and product portfolio in the pharmaceutical sector.
Why it matters
This deal represents ongoing consolidation in the Indian pharmaceutical industry, aimed at enhancing regulatory compliance and global market access.
RPG Life Sciences is acquiring the active pharmaceutical ingredients (API) and intermediates business of Raghava Life Sciences for ₹135 crore.
Only business assets are being acquired and not shares of any entity, RPG Life Sciences said, announcing recent signing of a business transfer agreement (BTA) for the acquisition on a going-concern basis through a slump sale through wholly owned subsidiary RPG Active Pharma.
The acquisition is the next step in RPG Active Pharma’s consolidation play based on a well-planned buy-and-build strategy to bolster organic growth and create an integrated, scaled API focused organization. Following the recent acquisition of Actis Generics, the latest transaction broadens its manufacturing base, product portfolio, regulatory capabilities and customer access across geographies.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in